Panacos Pharmaceuticals Inc. is pursuing parallel strategies to discover novel antiviral drugs and vaccines, with a particular focus on HIV's growing resistance to approved therapeutics. Its lead candidates are synthetic versions of compounds discovered through its natural products screening platform. The company is also searching for orally available inhibitors of viral fusion-the initial step in viral infection.